Abstracts tagged "prognostic factors"

Abstract Number: 1284 • ACR Convergence 2023
Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study
Kangping Huang¹, Mucong Li¹, Chen Yu¹, Nan Jiang¹, Jiuliang zhao¹, Qian Wang¹, Peng Yin², Xinping Tian¹, Mengtao Li¹ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Chinese Center for Disease Control and Prevention, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) poses significant challenges for patients in China due to prolonged disease duration prior to a definitive diagnosis, resulting in comorbidities and…
Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 0638 • ACR Convergence 2023
Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Zoe Brown¹, Dylan Hansen², Wendy Stevens³, Nava Ferdowsi⁴, laura ross⁵, Alannah Quinlivan⁶, Joanne Sahhar⁷, Gene-Siew Ngian⁷, Diane Apostolopoulos⁷, Jennifer G Walker⁸, Susanna Proudman⁹, Gim Gee Teng¹⁰, Andrea Hsiu Ling Low¹¹, Kathleen Morrisroe¹² and Mandana Nikpour¹³, ¹The University of Melbourne, Armadale, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁴St Vincents Hospital, Kew, Australia, ⁵St. Vincent's Hospital Melbourne, Fitzroy, Australia, ⁶St Vincent's Hospital Melbourne, Highett, Australia, ⁷Monash Health and Monash University, Clayton, Australia, ⁸Royal Adelaide Hospital, Adelaide, Australia, ⁹Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ¹⁰Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, ¹¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ¹²The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ¹³The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…
Abstract Number: 1285 • ACR Convergence 2023
PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, Clifton Bingham², Orit Schieir³, Marie-France Valois⁴, Gilles Boire⁵, Louis Bessette⁶, Janet Pope⁷, Diane Tin⁸, Carter Thorne⁹, Glen Hazlewood¹⁰, Carol Hitchon¹¹, Edward Keystone¹² and Vivian Bykerk¹³, ¹McGill University, Montreal, QC, Canada, ²Johns Hopkins Medicine, Baltimore, MD, ³McGill University, Montréal, QC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁷University of Western Ontario, London, ON, Canada, ⁸Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹³Hospital for Special Surgery, New York, NY
Background/Purpose: We have previously shown that PROMIS-29 physical (pain, fatigue) and emotional (depression, anxiety) symptom clusters can be used to identify 4 distinct early RA…
Abstract Number: 2214 • ACR Convergence 2023
Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis
Abhijeet Danve¹, Maureen Dubreuil², Swetha Ann Alexander³, Yuliya afinogenova⁴, Mohamad Bittar⁵, Alyssa Grimshaw⁶, Liana Fraenkel⁷, Michael LaValley⁸, Anand Kumthekar⁹, Jean liew¹⁰, Marina Nighat Magrey¹¹, Vikas Majithia¹², Sali Merjanah¹³, Hillary Norton¹⁴, Jessica A Walsh¹⁵ and Atul Deodhar¹⁶, ¹Yale University School of Medicine, Glastonbury, CT, ²Department of Rheumatology, Boston University School of Medicine, Milton, MA, ³University of Utah Health, Salt Lake City, UT, ⁴Yale, Hamden, CT, ⁵The University of Tennessee Health Science Center, Memphis, TN, ⁶Yale University, New Haven, CT, ⁷Berkshire Health Systems, Lenox, MA, ⁸Boston University School of Public Health, Arlington, MA, ⁹Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ¹⁰Boston University, Boston, MA, ¹¹Case Western Reserve University, University Hospitals, Cleveland, OH, ¹²Mayo Clinic Florida, Jacksonville, FL, ¹³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ¹⁴Inspire Santa Fe Rheumatology, Santa Fe, NM, ¹⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ¹⁶Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Lack of timely referral of suspected axSpA patients to rheumatologists contributes to misdiagnosis, delayed treatment, and poor outcomes. Currently there are no formal guidelines…
Abstract Number: 0643 • ACR Convergence 2023
Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Hilde Jenssen Bjørkekjær⁵, Cathrine Brunborg⁶, Cosimo Bruni⁷, Christian Clarenbach⁸, Phuong Phuong Diep⁹, Rucsandra Dobrota⁷, Michael Durheim¹⁰, Muriel Elhai¹¹, Thomas Frauenfelder¹², Suzana Jordan⁷, Emily Langballe¹³, Oyvind Midtvedt¹, Carina Mihai⁷, Oyvind Molberg¹⁴ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁶Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ¹⁰Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹¹University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹²Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹³Universitetet i Oslo, Oslo, Norway, ¹⁴Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: In clinical practice, we often wait for progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) to initiate or escalate therapy. Similarly, progressive…
Abstract Number: 1300 • ACR Convergence 2023
Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression
Kou Katayama¹, Takanobu Okubo², Toshikazu Sato¹, Kitaru Tanaka³, Tomoki Kawahata³, Yuichi Makino⁴ and Hiroshi Ito⁵, ¹Department of Orthopedic Surgery, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ²Department of Radiology, Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ³Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan, ⁴Department of Medicine, Division of Rheumatology, Asahikawa Medical University Hospital, Asahikawa, Japan, ⁵Department of orthpedic surgery, Asahikawa Medical University, Asahikawa, Japan
Background/Purpose: Rapid radiographic progression (RRP) is selected as one of the risk factors for difficult- to- treat RA, which needs to be resolved as soon…
Abstract Number: 2224 • ACR Convergence 2023
Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes
FERNANDO MONTERO¹, Laura Berbel Arcobé², Karen Carpio Astudillo¹, Jose Maria Bellón³ and Xavier Juanola Roura⁴, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²H.U. Bellvitge, Barcelona, Spain, ³Gregorio Marañón Health Research Institute, Madrid, Spain, ⁴Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…
Abstract Number: 036 • 2023 Pediatric Rheumatology Symposium
Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease
Germana Nardini¹, Claudia Bracaglia², Denise Pires Marafon¹, Emanuela Sacco³, Arianna De Matteis¹, Ivan Caiello¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Manuela Pardeo², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³Fondazione Casa Sollievo della Sofferenza, Pediatria, San Giovanni Rotondo, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare autoinflammatory disease of unknown etiology. Several uncontrolled studies showed that early treatment with anakinra is associated…
Abstract Number: 0432 • ACR Convergence 2022
Predictive Factors of Eosinophilic Granulomatosis with Polyangiitis Long-term Evolution: Data from a European Cohort
Matthias Papo¹, Pauline Martinot², Renato A. Sinico³, Vitor Teixeira⁴, Nils Venhoff⁵, Maria-Letizia Urban⁶, Juliane Mahrhold⁷, Francesco Locatelli⁸, Giulia Cassone⁹, Franco Schiavon¹⁰, Benjamin Seeliger¹¹, Thomas Neumann¹², Claus Kroegel¹³, Matthieu Groh¹⁴, Chiara Marvisi¹⁵, Maxima Samson¹⁶, Thomas Barba¹⁷, David Jayne¹⁸, Arianna Troilo¹⁹, Jens Thiel²⁰, Bernhard Hellmich²¹, Sara Monti²², Carlomaurizio Montecucco⁸, Carlo Salvarani²³, Jean-Emmanuel Kahn²⁴, Cecile-Audrey DUREL²⁵, Luc Mouthon²⁶, Loïc Guillevin²⁶, Giacomo Emmi²⁷, Augusto Vaglio²⁸, Raphaël Porcher²⁹ and Benjamin Terrier²⁶, ¹Service De Médecine Interne - Hôpital Cochin, Paris, France, ²Centre of Research in Epidemiology and Statistics, Université de Paris, Paris, Île-de-France, France, Paris, ³Department of Medicine and Surgery, Università degli Studi di Milano – Bicocca, Italy, Milano, Italy, ⁴Hospital de Faro, CHUA, Lisbon, Portugal, ⁵Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁶Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy, ⁷Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ⁸Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, ⁹Università di Modena e Reggio Emilia, Modena, Italy, ¹⁰Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, ¹¹Department of Respiratory Medicine, Hannover Medical School, Wermsdorf, Germany, ¹²Kantonsspital St. Gallen, St. Gallen, Switzerland, ¹³Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, ¹⁴Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, ¹⁵Università di Modena e Reggio Emilia and National Institute of Arthritis & Musculoskeletal & Skin Diseases, National Institutes of Health, Bethesda, MD, ¹⁶Dijon University Hospital, Dijon, France, ¹⁷Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, ¹⁸University of Cambridge, Cambridge, United Kingdom, ¹⁹Department of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²⁰University Hospital Freiburg, Freiburg, Germany, ²¹Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany, ²²Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ²³Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ²⁴Service de médecine interne - Hôpital Ambroise Paré, AP-HP, Boulogne-Billancourt, France, ²⁵CHU Lyon, Lyon, France, ²⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁷Azienda Ospedaliero Universitaria Careggi, Firenze, Italy, ²⁸Azienda Ospedaliero Universitaria Meyer, Parna, Italy, ²⁹Université Paris Cité, Hôtel-Dieu, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Glucocorticoids (GCs) frequently control the…
Abstract Number: 1262 • ACR Convergence 2022
Clinical and Ultrasound-based Composite Disease Activity Indices and Radiographic Progression in Rheumatoid Arthritis
Irina Gessl¹, Thomas Deimel¹, Paul Studenic¹, Giorgio Tamborrini², Pascal Zufferey³, Daniel Aletaha⁴, Burkhard Moeller⁵ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Ultrasound Center and Institute for Rheumatology, Zürich, Switzerland, ³HFR, Fribourg, Switzerland, ⁴Medical University Vienna, Wien, Austria, ⁵Inselspital - University Hospital Bern, Bern, Switzerland
Background/Purpose: Musculoskeletal ultrasound (US) has been reported to predict radiographic progression in rheumatoid arthritis (RA). The aim of the study was to test the predictive…
Abstract Number: 2204 • ACR Convergence 2022
Interosseous Tendon Inflammation in the Hands: A Novel Feature of Developing Rheumatoid Arthritis? Results from a Large MRI Study in Clinically Suspect Arthralgia
Bastiaan van Dijk¹, Hanna van Steenbergen¹, Monique Reijnierse², Sarah J.H. Khidir², Lambertus Wisse¹, Marco deRuiter¹ and Annette van der Helm-van Mil³, ¹Leiden University Medical Centre (LUMC), Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Inflammation around the tendons of hand interosseous muscles (interosseous tendon inflammation; ITI) on MRI was recently reported for the first time in rheumatoid arthritis…
Abstract Number: 0458 • ACR Convergence 2022
Predictive Models for Thromboembolic Events in Giant Cell Arteritis: A US Veterans Health Administration Population-Based Study
Despina Michailidou¹, Tianyu Zhang², Andreas Diamantopoulos³, Pavlos Stamatis⁴ and Bernard Ng⁵, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Akershus University Hospital, Lørenskog, Norway, ⁴Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden, Larissa, Larisa, Greece, ⁵Rheumatology Section, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is an independent risk factor for thromboembolic events. The purpose of our study was to identify prognostic factors for thromboembolic…
Abstract Number: 1264 • ACR Convergence 2022
Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
Kerem Abacar¹, Rabia Ergelen², Fatma Temiz², Yasin Yildiz², Tulin Ergun³, Haner Direskeneli⁴ and Fatma Alibaz-Oner¹, ¹Marmara University, Rheumatology, Istanbul, Turkey, ²Marmara University, School of Medicine, Departmant of Internal Medicine, Istanbul, Turkey, ³Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: We reported the first controlled ultrasound study showing increased common femoral vein(CFV) thickness in Behçet's Disease(BD),1 and showed that this is a distinctive feature…
Abstract Number: 0469 • ACR Convergence 2022
Factors Associated with Corticosteroid Dosing in the Management of Giant Cell Arteritis
Loukas Kakoullis and Shiv Sehra, Mount Auburn Hospital, Cambridge, MA
Background/Purpose: Corticosteroids are the cornerstone of therapy in patients with giant cell arteritis (GCA). Tapering regiments vary considerably in both dose and duration, while relapses…

« Previous Page
1
…
8
9
10
11
12
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].